GlassScriptPhysician profile
Nirav Nagarsheth
NPI 1457858318
$7,819.02
in general payments reported to CMS, 2019-2025
27 companies · $3,698 in 2025
The $3,698 reported for 2025 was more than what 82% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $713 · 2024: $3,408 · 2025: $3,698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,655 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,654.80 |
| Education | $164.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,840.46 | 2023-2025 | Krystexxa, Otezla, Otezla |
| Abbvie INC. | $1,337.81 | 2023-2025 | |
| Ucb, INC. | $845.07 | 2023-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $553.03 | 2023-2025 | Tremfya |
| Glaxosmithkline, LLC. | $547.16 | 2023-2025 | Benlysta |
| Lilly USA, LLC | $264.85 | 2023-2025 | Taltz |
| Novartis Pharmaceuticals Corporation | $264.00 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $261.54 | 2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $259.61 | 2024-2025 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.11 | 2023-2025 | Ofev, Cyltezo |
| Genzyme Corporation | $218.50 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $166.51 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $151.32 | 2023-2025 | Orencia |
| Kyowa Kirin, INC. | $139.32 | 2024-2025 | Crysvita |
| Radius Health, INC. | $123.71 | 2023-2025 | Tymlos |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hospira, INC. | $104.36 | 2024-2025 | |
| Pfizer INC. | $93.19 | 2023-2024 | |
| Aurinia Pharma U.S., INC. | $80.59 | 2024-2025 | Lupkynis |
| Sandoz INC. | $76.06 | 2023-2025 | Hyrimoz |
| Genentech USA, INC. | $65.67 | 2024-2025 | Actemra |
| Ani Pharmaceuticals, INC. | $46.55 | 2024-2025 | Purified Cortrophin Gel |
| Janssen Scientific Affairs, LLC | $33.89 | 2024-2025 | Tremfya |
| Horizon Therapeutics Plc | $30.09 | 2023 | Krystexxa |
| Organon LLC | $29.35 | 2024 | |
| Octapharma USA, INC. | $26.94 | 2025 | Octagam Immune Globulin (Human) |
| Alvogen INC | $20.45 | 2025 | Teriparatide |
| Celgene Corporation | $19.88 | 2024 | Orencia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirav Nagarsheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.